The 3 Worst-Performing Big Pharma Stocks of 2013
Upcoming SlideShare
Loading in...5
×
 

The 3 Worst-Performing Big Pharma Stocks of 2013

on

  • 4,687 views

The S&P 500 soared more than 32% in 2013, and several big pharma companies also soared. Some, however -- namely Sanofi (NYSE: SNY), Novo Nordisk (NYSE: NVO), and Eli Lilly (NYSE: ...

The S&P 500 soared more than 32% in 2013, and several big pharma companies also soared. Some, however -- namely Sanofi (NYSE: SNY), Novo Nordisk (NYSE: NVO), and Eli Lilly (NYSE: LLY) -- significantly trailed their peers. To find out why these stocks stumbled last year, and what they need to do to soar this year, click on the slideshow below.

Statistics

Views

Total Views
4,687
Views on SlideShare
1,281
Embed Views
3,406

Actions

Likes
9
Downloads
21
Comments
1

33 Embeds 3,406

http://www.fool.com 3174
http://www.dailyfinance.com 150
http://m.fool.com 43
http://192.168.6.179 4
http://www.barchart.com 4
https://www.facebook.com 2
http://translate.googleusercontent.com 2
http://www.sfgate.com 2
https://m.facebook.com&_=1390764802355 HTTP 1
https://m.facebook.com&_=1390576100204 HTTP 1
https://m.facebook.com&_=1390574973769 HTTP 1
https://m.facebook.com&_=1390581984894 HTTP 1
https://m.facebook.com&_=1390590927940 HTTP 1
https://m.facebook.com&_=1390596881584 HTTP 1
https://m.facebook.com&_=1390607037779 HTTP 1
https://m.facebook.com&_=1390607005014 HTTP 1
https://m.facebook.com&_=1390611055968 HTTP 1
https://m.facebook.com&_=1390614408314 HTTP 1
https://m.facebook.com&_=1390614423021 HTTP 1
https://m.facebook.com&_=1390570142078 HTTP 1
https://m.facebook.com&_=1390568851165 HTTP 1
http://cms.fool.com 1
https://m.facebook.com&_=1390565040095 HTTP 1
https://m.facebook.com&_=1390565070351 HTTP 1
https://m.facebook.com&_=1390565048895 HTTP 1
https://m.facebook.com&_=1390565027140 HTTP 1
https://m.facebook.com&_=1390565938909 HTTP 1
https://m.facebook.com&_=1390565963953 HTTP 1
https://m.facebook.com&_=1390568746188 HTTP 1
https://m.facebook.com&_=1390568824308 HTTP 1
https://m.facebook.com&_=1390568832333 HTTP 1
https://m.facebook.com&_=1390568797647 HTTP 1
http://www.google.com 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

The 3 Worst-Performing Big Pharma Stocks of 2013 The 3 Worst-Performing Big Pharma Stocks of 2013 Presentation Transcript

  • The 3 Worst-Performing Big Pharma Stocks of 2013
  • The Big Pharma Industry • Stocks across the pharmaceutical space performed extraordinarily well in 2013. • Bristol-Myers Squibb and AbbVie delivered incredible returns to shareholders, but others lagged far behind the S&P 500. • What were the three worst-performing big pharma stocks of 2013?
  • #3 Sanofi SNY Total Return Price data by YCharts
  • What Stalled Sanofi’s Progress? • Revenue contracted toward the end of 2012 and for the first half of 2013. Sanofi also suffered particularly disappointing second quarter results due to generic competition. The company lowered its 2013 guidance and shares tumbled. • However, sales picked up in Q3 and the worst of the patent cliff seems to be over. Sanofi has several promising drug candidates in its pipeline, and, despite the FDA rejection of multiple sclerosis drug Lemtrada, looks set to return to solid growth over the longterm
  • #2 Novo Nordisk NVO Total Return Price data by YCharts
  • What Stalled Novo’s Progress? • Diabetes specialist Novo Nordisk lagged far behind its peers last year. • Shares tumbled after the FDA rejected its insulins Tresiba and Ryzodeg in February. Tresiba was meant to help Novo compete with Sanofi’s Lantus, the leader in the long-acting insulin market. The company must run more clinical trials before Tresiba and Ryzodeg can be re-considered for FDA approval.
  • What Stalled Novo’s Progress? • Despite strong sales growth for its GLP-1 analog Victoza, shares tumbled in Q3 after the company missed sales and profit estimates. • Novo will need to have strong sales growth for Victoza and its insulin products, as well as positive clinical results from its experimental drugs, to perform well this year.
  • #1 Eli Lilly LLY Total Return Price data by YCharts
  • Why Eli Lilly Stumbled • Eli Lilly shareholders had a bumpy ride in 2013. • The company’s impressive line-up of blockbuster drugs is eroding as patents start to expire. • Zyprexa lost market exclusivity in 2012 and had a negative impact on the company’s top-line last year. • Cymbalta, Lilly’s best-selling drug, lost patent protection near the end of last year. Evista is also set to lose patent protection in March 2014
  • Why Eli Lilly Stumbled • The company is slashing $1 billion from its R&D budget in an effort to soften the blow from these patent expirations. • However, the key to getting investors excited about its long-term potential is to release stellar clinical trial data from late-stage candidates and get FDA approvals for drugs such as dulaglutide and ramucirumab.
  • Looking ahead … Our Top Stock Pick for 2014